LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

DexCom Inc

Lezárt

SzektorEgészségügy

69.73 1.19

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

68.85

Maximum

71.01

Fő mutatók

By Trading Economics

Bevétel

-68M

200M

Értékesítés

-68M

1.2B

P/E

Szektor átlag

29.644

50.958

Egy részvényre jutó nyereség

0.56

Profit margin

16.738

Munkavállalók

11,000

EBITDA

-52M

337M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+19.86% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. júl. 29.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

3B

27B

Előző nyitás

68.54

Előző zárás

69.73

Hangulat hírek alapján

By Acuity

18%

82%

35 / 342 Rangsor szerint Healthcare

DexCom Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Rólunk DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat